Henry Ssenyondo
ID:
|
Maternal Antibody in Milk After Group B Streptococcus Vaccination in Uganda: MAMA study
REFNo: HS1986ES
General Objective
• To determine the concentration of antibody transferred in breastmilk following vaccination with Group B Streptococcal vaccine
Specific Objectives
• To determine the anti-GBS (anti-Alp1N, Alp2N, AlpCN and RibN) Immunoglobulin A (IgA) concentrations in the colostrum of women following vaccination with a GBS-containing vaccine or placebo in pregnancy.
• To determine the total IgA and Immunoglobulin G (IgG) concentrations in the colostrum and breastmilk of women at less than 48 hours, 28 (+/-4 days) and 56 (+/- 6 days) days after delivery following vaccination with a GBS-containing vaccine or placebo in pregnancy.
• To determine the anti-GBS (antiAlp1N, Alp2N, AlpCN and RibN) IgA concentrations in the breastmilk of women at 28 (+/-4 days) and 56 (+/- 6 days) days after delivery following vaccination with a GBS-containing vaccine in pregnancy.
• To determine the anti-GBS (antiAlp1N, Alp2N, AlpCN and RibN) IgG concentrations in the colostrum and breastmilk of women at less than 48 hours, 28 (+/-4 days) and 56 (+/- 6 days) days after delivery following vaccination with a GBS-containing vaccine in pregnancy.
|
Kampala, Kawempe Central
|
Uganda |
2022-09-21 21:13:49 |
2025-09-21 |
50 |
Women
18 to 40 years
All tribes |
Makerere University |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Eugene Ruzagira
ID: UNCST-2023-R008282
|
A phase Ib study to assess the safety and immunogenicity of a recombinant adenovirus-based vaccine against plague in Uganda
REFNo: HS2387ES
Primary
To investigate safety and tolerability of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine in healthy African adults aged 18 to 49 residing in Uganda, when given as one or two dose(s) intramuscularly with different prime-boost intervals
Secondary
To determine the immunogenicity of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine, in healthy African adults aged 18 to 49 years residing in Uganda when given as one or two dose(s) intramuscularly with different prime-boost intervals.
Tertiary
Exploratory immunogenicity assays to determine the immunogenicity of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine, in healthy African adults aged 18 to 49 years residing in Uganda when given as one or two dose(s) intramuscularly with different prime-boost intervals.
|
Masaka, KATWE
|
Uganda |
2022-09-12 18:28:42 |
2025-09-12 |
36 |
Healthy male or female African adults aged 18-49 years, inclusive. Inclusion and exclusion criteria are as follows:
Inclusion Criteria
• Willing and able to give informed consent for participation in the trial.
• Male or female aged between 18-49 years inclusive at enrolment (first vaccination visit, V1)
• In good health as determined by
o Medical history (as determined by verbal medical history)
o Physical examination
o Clinical judgment of the investigators
• Female participants of childbearing potential must be willing to ensure that they use effective contraception during the trial and for 3 months after the last vaccination.
• Female participants of childbearing potential must have a negative pregnancy test on the day(s) of screening and vaccination.
• Able to attend the scheduled visits and to comply with all study procedures
• Agrees to refrain from donating blood for the duration of the trial
• Clinically acceptable baseline screening results (includes vital signs, physical examination, urinalysis, and laboratory results)
• In the Investigator’s opinion, is able and willing to comply with all trial requirements.
Exclusion Criteria
The participant may not be enrolled in the study if any of the following apply:
• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
• History of significant organ/system disease that could interfere with trial conduct or completion. This includes a known history of significant disease in the following:
o Cardiovascular disease including congenital heart disease, previous myocardial infarction, valvular heart disease (or history of rheumatic fever), previous bacterial endocarditis, history of cardiac surgery (including pacemaker insertion), personal or family history of cardiomyopathy or sudden adult death
o Respiratory disease such as uncontrolled asthma and chronic obstructive pulmonary disease
o Endocrine disorders such as diabetes mellitus and Addison’s disease
o Significant renal or bladder disease
o Biliary tract disease
o Gastro-intestinal disease such as inflammatory bowel disease, major abdominal surgery within the last two years, coeliac disease and liver disease (including hepatitis B or C infection)
o Neurological disease such as seizures and myasthenia gravis
o Haematological problems such as coagulation problems or anaemia (haemoglobin < 12.5g/dL for females and < 13.5 g/dL and for males)
o Metabolic disease such as glucose-6-phosphate dehydrogenase deficiency
o Psychiatric illness requiring hospitalisation or depression if severity is deemed clinically significant by the study Investigators
o Known or suspected drug and/or alcohol misuse
o Non-benign cancer, except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ
• Any other significant disease or disorder which, in the opinion of the Investigator, could:
o Put the participant at risk because of participation in the trial
o Influence the result of the trial
o Impair the participant’s ability to participate in the trial
• History of allergy to a vaccine or any component of the vaccines used in this study
• History of anaphylaxis
• Have any known or suspected impairment or alteration of immune function, resulting from, for example:
o Congenital or acquired immunodeficiency
o Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
o Autoimmune disease
o Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy (including for more than 7 days consecutively within the previous 3 months).
• Receipt of immunoglobulins or any blood product transfusion within 3 months prior to enrolment
• Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
• Weight <50kg or a body mass index (BMI) greater than 35kg/m2.
• Known history of previous occurrence of disease caused by Y. pestis or receipt of a vaccine against plague
• Current active participation in another research study involving an investigational product (including receipt of an IMP within last 30 days) or where involvement in this study could impact the results
• It is not in the best interest of the volunteer to participate in the trial, in the opinion of the Investigator.
|
University of Oxford |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Gorretti Nassali
ID:
|
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR?POSITIVE, HER2 NEGATIVE EARLY BREAST CANCER
REFNo: HS2133ES
Primary objective:
To demonstrate superiority of giredestrant over the control treatment
Secondary objectives:
1. To evaluate the efficacy of giredestrant compared with TPC
2. To evaluate the safety of giredestrant compared with TPC
3. To characterize giredestrant pharrmacokinetics (PK)
4. To evaluate health status utility scores of participants treated with giredestrant compared with TPC
5. To evaluate the efficacy of giredestrant compared with TPC
6. To evaluate the tolerability of giredestrant compared with TPC
7. To identify and/or evaluate biomarkers that are predictive of response to giredestrant
|
Kampala, mulago
|
Uganda |
2022-09-06 14:14:37 |
2025-09-06 |
Approximately 4700 participants will be screened to achieve random assignment in 1:1 ratio to study treatment of 4100 randomized participants for an estimated total of 2050 randomized participants per |
Approximately 4100 participants with medium- and high-risk Stage I?III histologically confirmed ER? and HER2? EBC will be enrolled during the global enrollment phase of this study. After completion of the global enrollment phase, additional participants |
F. Hoffmann-La Roche Ltd Grenzacherstrasse 124 4070 Basel, Switzerland |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
ASSESSMENT OF USABILITY OF THE WONDFO HIV SELF-TEST ONE STEP HIV 1/2 WHOLE BLOOD/SERUM/PLASMA TEST BY UNTRAINED USERS
REFNo: HS1878ES
To evaluate the ability to correctly comprehend key messaging from device packaging and labelling, including the Instructions for Use.,The evaluation of untrained users’ and their interaction with the device in terms of effectiveness and efficiency, i.e. successful / unsuccessful completion and difficulty of the critical steps as per the Instructions for Use,To evaluate the ability of untrained users to obtain an accurate HIV test result using the Wondfo HIV Self-Test.,
|
Buhweju, Nsika
Wakiso, Central
Bulambuli, Bulambuli Town Council
Mbale, Mbale City
|
Uganda |
2022-08-30 10:24:48 |
2025-08-30 |
100 |
All participants will be > 18 years old of all Sex from the bamasaba region |
Central Public Health Laboratories |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Prudence Atukunda Friberg
ID: UNCST-2023-R006221
|
The NutriMind Trial: A low-cost randomized trial combining a healthy diet and psychotherapy to treat depressive symptoms among university students – The case of Uganda
REFNo: HS2146ES
The primary outcome is a mean reduction of 6 scores on the CES-D scale
• Biomarkers of metabolism (i.e. lipids, carbohydrates and hormones) will be measured in samples from blood, urine or saliva as appropriate and using standard methods.
• Biomarkers of inflammation (e.g. CRP, interleukins) and antioxidants will be measured in blood, urine or saliva as appropriate and using e.g. multiplex-techniques, immunolabelling methods and metabolomics.
• Microbiome will be analysed in samples from the oral cavity and from feces using established techniques (16S rRNA amplicon sequencing and reduced metagenome sequencing).
The combined intervention arm with MBCT and Diet will reduce depressive symptoms more than the control arm
Biomarkers of metabolism ( lipids, carbohydrates and hormones) measured in samples from blood, urine or saliva as appropriate and using standard methods
Biomarkers of inflammation ( CRP, interleukins) and antioxidants measured in blood, urine or saliva as appropriate and using multiples-techniques, immunolabelling methods and metabolomics
Microbiome will be analysed in samples from the oral cavity and from feces using established techniques ( 16rRNA amplicon sequencing and reduced metagenome sequencing)
|
Kampala, Makerere
|
Uganda |
2022-08-03 11:19:53 |
2025-08-03 |
200 |
The study population is university students with self reported depression symptoms as determined by Beck depression Inventory validated assessment tool. The partcipants will be aged range 19 and above both female and males will be included from all the tr |
University of Oslo |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Atupele Mlangwa Subira
ID:
|
PREVALENCE AND FACTORS ASSOCIATED WITH PROLONGED HOSPITAL STAY FOLLOWING CAESEREAN DELIVERY AT MBARARA REGIONAL REFERRAL HOSPITAL
REFNo: NS383ES
2. To determine the factors associated with prolonged hospital stay following caesarean delivery at MRRH,1. To determine the prevalence of prolonged hospital, stay following caesarean delivery at MRRH,To determine the prevalence and factors associated with prolonged hospital stay following caesarean delivery at MRRH,
|
Mbarara, Medical Cell
|
Tanzania |
2022-07-26 11:29:37 |
2025-07-26 |
427 |
Adult women delivered by caesarian section at Mbarara Regional Referral Hospital |
Atupele Subira Mlangwa |
Natural Sciences |
Clinical Trial |
Degree Award |
.jpg)
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
REFNo: HS2173ES
8. To validate the ability of fertility biomarkers to diagnose and predict permanent loss of ovarian function, and to determine the impact of anti-cancer therapy on hormone levels,7. To evaluate health status utility scores of patients treated with atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,6. To identify and/or evaluate biomarkers that are predictive of response to atezolizumab and trastuzumab emtansine (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with acquired resistance to atezolizumab and trastuzumab emtansine, are associated with susceptibility to developing adverse events or can lead to improved adverse event monitoring or investigation (i.e., safety biomarkers), can provide evidence of atezolizumab and trastuzumab emtansine activity (i.e., pharmacodynamic biomarkers), or can increase the knowledge and understanding of disease biology and drug safety,5. To evaluate the immune response to atezolizumab and trastuzumab emtansine,4. To characterize the PK profiles of atezolizumab and trastuzumab emtansine when given in combination,3. To evaluate the safety of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,2. To evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in the PRO-evaluable analysis set,1. The secondary efficacy objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population and PD-L1-positive population,The primary objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population (all comers) and the PD-L1-positive population (defined as all patients from the ITT population with a centrally assessed PD-L1-positive status [i.e., PD-L1 status of IC1/2/3] at randomization),
|
Kampala, Mulago
|
Uganda |
2022-07-21 11:00:02 |
2025-07-21 |
30 |
This study will enrolling women with a primary diagnosis of HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease i |
Nixon Niyonzima |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Moffat Nyirenda Joha
ID: UNCST-2020-R019333
|
Development and Evaluation of an Integrated Community-based Management Model for HIV, Diabetes, and Hypertension in Tanzania and Uganda (The INTE-COMM study)
REFNo: HS2278ES
To determine the effectiveness of community-based integrated management of HIV, diabetes, and hypertension in comparison to clinic-based integrated management of these conditions in terms of patient outcomes, acceptability, and potential cost-effectiveness.
|
Kampala, N/A
Wakiso, N/A
Mpigi, N/A
Lwengo, N/A
|
Malawi |
2022-07-13 16:33:33 |
2025-07-13 |
1,736 participants |
Assuming an intra-class coefficient, rho of 0.02, we need to form 116 groups, each comprising 12 persons (8 with diabetes or hypertension and 4 with HIV). This will provide over 80% power to detect an absolute difference in risk of diabetes and hypertension control of 10% (i.e. 50% versus 60% achieving good control in the 2 arms would be statistically significant at the 5% two-sided significance level). Power will be very high for differences larger than this. For the HIV viral suppression endpoint, we assume that viral suppression is close to 90% and that the primary aim is to show non-inferiority with the community-care arm (and secondary analyses will compare superiority). The trial will have over 80% power to show non-inferiority with a margin of delta= 8.5%, 7.5%, and 5.5% assuming viral suppression is 85%, 90% and 95% respectively. To allow for losses to follow-up, our target for enrolment is 124 groups each comprising 14 participants (i.e. a total of 1,736 participants). |
National Institute of Health Research (NIHR) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jackson Mukonzo
ID: UNCST-2021-R013916
|
Ivermectin-artemisinin Combination Therapy for Eradication of Malaria
REFNo: HS2081ES
Main Objective:
1. To investigate the effect of ivermectin adjunct therapy on household transmissibility of malaria from malaria-infected patients receiving artemether /lumefantrine
Specific objectives
1. To determine the household malaria transmissibility within one month of IVN and
artemether / lumefantrine therapy.
2. To determine the structural similarity of the nanopore plasmodium sequences between
infecting plasmodium species isolated from the index patient and other household malaria
positive patients.
3. To assess the safety of ivermectin-artemether/lumefantrine in malaria-infected patients.
|
Kasese, NA
|
Uganda |
2022-07-13 16:29:55 |
2025-07-13 |
110 Participants |
Adults aged 18 to 65 years of age, both males and females. No specific tribe in our inclusion criteria but most of the study participants are expected to be Bakonzo given that the study site is Kasese. |
MAKERERE UNIVERSITY RESEARCH AND INNOVATION FUND |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Andrew Mujugira
ID: UNCST-2019-R000871
|
CHOICE-BASED PrEP DELIVERY FOR TRANSGENDER PEOPLE IN UGANDA
REFNo: HS2316ES
Aim 1: Identify PRECEDE factors that influence PrEP implementation for transgender people in Uganda.
Guided by the PRECEDE-PROCEED model, which is widely used for public health interventions, we will analyze previously collected qualitative data from four TGP studies and also conduct two new focus groups with TGP and providers to identify predisposing, reinforcing, and enabling factors that may impact implementation of choice-based PrEP. A stakeholder workshop anchored in good participatory practice will discuss results of the qualitative research and guide design of the optimal choice-based PrEP delivery model for Aim 2.
Aim 2: Offer PrEP choice to transgender people in a DSD model and evaluate implementation and effect on PrEP use (PROCEED).
We will offer choice of CAB-LA or oral PrEP, and choice of facility or community delivery (with option to switch), to 300 HIV-negative TGP with follow-up for 24 months. Adverse events, product switching, and trajectories of choice over time will be monitored and documented. Persistence on CAB LA and oral PrEP will be compared during the choice period, and with a historical cohort without PrEP choice (ClinicalTrials.gov, NCT04491422). Primary outcomes are choice of PrEP option & delivery model, adherence, and persistence.
Aim 3: Use mixed methods to evaluate how choice influences PrEP use among TGP (PROCEED).
Inductive and deductive analyses based on in-depth interviews with purposively sampled PrEP users (n=50) and providers (n=10) will be used to explain “how” and “why” choice did or did not work and interpret implementation data from Aim 2. Choice preferences will be assessed via structured questionnaires.
Aim 4: Estimate cost implications associated with integrating CAB LA into HIV programs.
We will conduct health system versus client cost analyses to inform budgeting. Costs incurred and averted will be estimated using activity-based micro-costing, study budget, and the literature. Costs and modeled outcomes will be combined to estimate budget impact with PrEP persistence at 6 and 12 months.
|
Wakiso, Kasangati
|
Uganda |
2022-06-28 16:44:09 |
2025-06-28 |
420 |
Population: Trans women and men (up to 300 participants)
Eligibility Eligible TGP must be aged ≥18, weigh ≥35kg, be interested in taking PrEP, at high risk for sexually acquiring HIV (i.e., any self-report of condomless sex, multiple partners, stimulant drug use or STIs) in the prior six months, and eligible for PrEP in accordance with Uganda National PrEP Guidelines
|
United States National Institute of Mental Health (R01 MH130208) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Agnes Nyabigambo
ID:
|
Effectiveness of clinic-based patient-led HPV DNA self-sampling among HIV-infected women in Uganda.
REFNo: HS2084ES
1. To assess the difference and associated factors of uptake of clinic-based compared to home-based HPV self-sampling approach among HIV infected women in rural Uganda.
2. To identify factors associated with the prevalence of HPV among HIV-infected women in rural Uganda.
3. To determine factors influencing sample viability HPV self-collected samples in clinic arm compared with home -based arm.
4. To explore the facilitators and barriers of clinic-based compared to home-based HPV self-sampling approaches among HIV-infected women in rural Uganda.
5. To estimate the cost-effectiveness of the clinic-based approach compared to the home-based HPV-DNA self-sampling among HIV-infected women in rural Uganda.
|
Luweero, Kasana
|
Uganda |
2022-06-08 15:13:10 |
2025-06-08 |
382 |
Women living with HIV aged 25-49 years. |
HEARD PhD Scholarship |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Joshua Muhumuza
ID:
|
Effect of chewing gum on duration of postoperative ileus following laparotomy for gastroduodenal perforations; a multi centre study.
REFNo: HS1665ES
i. To compare the time taken for post-operative ileus to resolve in the two groups.
ii. To compare the duration of hospital stay in the two groups.
iii. To determine other factors associated with the duration of post-operative ileus in the study population.
|
Kabarole, Central Division
Bushenyi, Central Division
Hoima, Central Division
|
Uganda |
2022-05-30 17:10:09 |
2025-05-30 |
52 participants |
All adult patients 18 years and above, male and female admitted to the surgical wards of study centre hospitals irrespective of tribe with gastric or duodenal perforations during the study period at will be the study population |
self sponsored |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Lisa Hartwig
ID:
|
The effectiveness of a behavioral science and design intervention for family savings on increased use of maternal health services and male involvement: a randomized controlled trial
REFNo: HS2194ES
To assess the effectiveness of a behavioral intervention designed to encourage financial savings for healthcare costs and birth preparedness among pregnant women and their partners in Uganda. To examine whether increased earmarked financial savings for healthcare costs leads to increased utilization of maternal health services and male involvement in maternal healthcare.
|
Kyotera, All
|
USA |
2022-05-23 9:28:49 |
2025-05-23 |
700 |
To be eligible for joining the study, the participants must fulfill the following eligibility criteria: (1) 18-49 years old, (2) Between 12-32 gestational weeks (pregnant female) OR partner of someone who is (male), (3) Own a mobile phone, (4) Has a regis |
The University of Tokyo |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Achilles Katamba
ID: UNCST-2019-R000540
|
Clinic versus Hotspot Active Case Finding and Linkage to TB Preventive Therapy (ACF/TPT) Strategy Evaluation for Tuberculosis
REFNo: HS2166ES
3. To estimate (using simulation) the impact of each intervention on diagnostic delays and TB prevalence.,2. To measure the implementation of hotspot-based and facility-based ACF + TPT, including the reach (number of individuals willing to be screened), implementation (measured via cascades of care), and maintenance (of effectiveness over time).,1. To compare the effectiveness of hotspot-focused versus facility-based ACF + linkage to TPT in terms of the number of individuals started on treatment for microbiologically confirmed TB in each community (i.e., reduction in undiagnosed TB prevalence, primary outcome) ,
|
Lwengo,
Masaka, Kalisizo
Mpigi, Nkozi
Mityana, Mityana
Bugiri, Bugiri
Butambala, Gombe
Iganga, Iganga
Kiboga, Kiboga
Lyantonde, Lyantonde
Mukono, Mukono
Kayunga, Kayunga
Luweero, Luwero
Mubende, Kassanda
Jinja, Kawoolo
Buikwe, Kawolo
Nakaseke, Nakaseke
|
Uganda |
2022-05-18 9:43:01 |
2025-05-18 |
80000 |
All willing participants 15 years and above of any sex and tribe residing with the study area |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Herbert Kayiga Kayiga
ID:
|
EFFECTIVENESS, ACCEPTABILITY AND UPTAKE OF EARLY VERSUS STANDARD INTRAUTERINE CONTRACEPTION FOLLOWING PROVISION OF FIRST TRIMESTER MEDICAL POST ABORTION CARE IN CENTRAL UGANDA
REFNo: HS2111ES
1. To determine the proportion of women who take up IUC after mPAC for 1st trimester incomplete abortion.
2. To compare the expulsion rates at six months between early versus standard IUC insertions post mPAC treatment for first trimester incomplete abortion.
3. To compare the IUC continuation rates at six months between early versus standard IUC insertion post mPAC treatment for first trimester incomplete abortion.
4. To explore the women and their spouses' perception on Long Acting Reversible Contraceptives (LARC) and IUC following mPAC treatment.
5. To explore the Healthcare providers' perception on LARC and IUC following mPAC treatment.
|
Wakiso, Kasangati
Kampala, Namirembe
Buikwe, Kawolo
Mpigi, Mpigi
Luweero, Luweero
Mukono, Kawolo
Masaka, Masaka
Mityana,
Kayunga,
Gomba,
|
Uganda |
2022-05-10 9:21:09 |
2025-05-10 |
2076 |
Women with first trimester incomplete abortion irrespective of tribe and nationality undergoing medical management will receive written and oral information about the study from the attending physician according to the principles of the Helsinki Declarati |
Prof Kristrina Gemzell |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
ANTHONY NUWA
ID: UNCST-2022-R011102
|
A hybrid effectiveness-implementation study to assess the effectiveness and chemoprevention efficacy of implementing seasonal malaria chemoprevention in five districts in Karamoja region, Uganda
REFNo: HS2212ES
5) To monitor the safety and torelabilty of DP as compared to SPAQ among children 6-59 months in Karamoja when used in SMC,4) To understand the SMC implementation model, determining process, costing and acceptability outcomes for the intervention,3) To investigate the presence and change of SPAQ and DP resistance markers over time as a result of SMC implementation ,2) To determine chemoprevention efficacy of SPAQ and DP when used for SMC in Karamoja region, Uganda, and the extent to which efficacy is impacted by drug resistance and/or drug concentrations. ,1) To determine the effectiveness of SMC with DP and SPAQ in terms of its reduction in incidence of malaria infection among children aged 3–59 months,Phase 2 of this study aims to test the feasibility, effectiveness and chemoprevention efficacy of SMC with SPAQ and DP in Karamoja region in Uganda, where malaria transmission is highly seasonal, and inform malaria policy in Uganda. Accelerated adoption and scale-up of SMC will support efforts to accelerate progress in malaria control in high-burden countries.,
|
Amudat, All
Nakapiripirit, All
Kotido,
Moroto, All
|
Uganda |
2022-05-05 11:23:22 |
2025-05-05 |
5550 |
3-59 months |
Bill and Melinda Gates Foundation |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
Performance evaluation of an improved point-of-care test (dual target) SAMBA HIV-1 qualitative test for early infant diagnosis of HIV-1 infection in resource-poor healthcare settings
REFNo: HS2219ES
To verify the field performance (sensitivity and specificity) of the improved, dual-target SAMBA II HIV-1 Qual Test against routine Cobas Ampliprep/Taqman HIV-1 Qualitative Test Version 2.0 (DBS)- for early diagnosis of HIV-1 in exposed infants and adults. In addition, discrepant results will be analysed using Cepheid Xpert HIV-1 Qual ,
|
|
Uganda |
2022-05-04 11:32:24 |
2025-05-04 |
0 |
Infants and Adults, between 1.5 months of age and all adults of all tribes |
Diagnostics for Real World (DRW) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Evaluation of the Safety , Efficacy and Stability of Sangatraz®-125 & Sangatraz®-250: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricides Field Trial
REFNo: A186ES
General objectives
To determine the efficacy, safety and stability of Sangatraz®-125 & Sangatraz®-250(Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve ) when applied onto cattle by hand spraying and plunge dipping for tick control.
Specific objectives
The specific objectives of this acaricide field trial will to to determine;
i.efficacy of Sangatraz®-125 & Sangatraz®-250 when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.safety of Sangatraz®-125 & Sangatraz®-250 when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of Sangatraz®-125 & Sangatraz®-250 when applied onto cattle by plunge dipping for tick control.
|
Mayuge, Musoli
Mayuge, Wabulungu ward
Mayuge, Katonte
Mayuge, Nkombe
Gomba, Madu Parish
Gomba, Kyayi Parish
,
|
Uganda |
2022-04-25 |
2025-04-25 |
n= 1,579 |
Cattle on 10 farms [5 farms in Gomba District and the other 5 from Mayuge District]. These will be both female and males above 2 months of age. All cattle breeds will be recruited |
Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ |
Agricultural Sciences |
Clinical Trial |
Non-degree Award |
|
Etheldreda Nakimuli-Mpungu
ID: UNCST-2020-R014808
|
Tele-Psychotherapy for Youth using Mobile Phones during Covid-19 Pandemic
REFNo: HS2106ES
1. We aim to conduct online and community-based participatory qualitative research to obtain information on the potential usefulness of individual tele-support psychotherapy in addressing depression during the Covid-19 pandemic.
2. We will compare the effectiveness of individual tele-support psychotherapy (TSP) delivered by trained lay counsellors in combination with standard mental health services (SMHS) for depression with use of SMHS alone.
3. We aim to compare the effects of TSP combined with SMHS and SMHS alone on other psychosocial variables including self-esteem, anxiety, alcohol and substance use, social support, stigma, number of disability days, asset possession, poverty indices, and cost-effectiveness measures.
4. To conduct a process evaluation of trial activities informed by Linnan and Steckler’s process evaluation frameworks to specifically determine indicators of feasibility, acceptability, fidelity, and to explore causal mediating processes and contextual influences
5. We will also explore whether or not the effects of TSP and SMHS are moderated by alcohol and drug use.
6. We shall explore whether the strength of a therapeutic relationship will mediate the effects of TSP and SMHS on depression
|
Kampala, Makerere
Kampala, Kamwokya Parish
Kampala, Naguru Ii Parish or Go down
|
Uganda |
2022-04-21 |
2025-04-21 |
300 |
To be eligible for the study, each participant must be 15-30 years old, diagnosed with significant depression symptoms assessed with the self reporting questionnaire, residing in Naguru Go-down and Kamwokya slums, or Makerere University campus. |
USAID (DIV) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nahwera Loyce
ID:
|
EFFECTS OF 12-WEEKS AEROBIC DANCE ON BLOOD PRESSURE, PERCENT BODY FAT AND hs-CRP IN HYPERTENSIVE PATIENTS ATTENDING KYAMBOGO MEDICAL CENTRE, UGANDA
REFNo: HS2202ES
1. To establish the baseline systolic and diastolic blood pressure, percent body fat and hs-CRP levels in stage 1 hypertensive patients attending Kyambogo University Medical Centre in Kampala, Uganda.
2. To determine the effect of a 12-week aerobics dance programme on Systolic Blood Pressure (SBP) levels in stage 1 hypertensive patients attending Kyambogo University Medical Centre in Kampala, Uganda.
3. To determine the effect of a 12-week aerobics dance programme on Diastolic Blood Pressure (DBP) levels in stage 1 hypertensive patients attending Kyambogo University Medical Centre in Kampala, Uganda.
4. To establish the effect of a 12-week aerobics dance programme on percent body fat in stage 1 hypertensive patients attending Kyambogo University Medical Centre in Kampala, Uganda.
5. To determine the effect of a 12-week aerobics dance programme on hs-CRP levels in stage 1 hypertensive patients attending Kyambogo University Medical Centre in Kampala, Uganda.
|
Kampala, Kyambogo
|
Uganda |
2022-04-19 |
2025-04-19 |
76 participants ( 34 in both experimental and control group) |
The target population will be stage 1 hypertensive patients attending KUMC. The study focuses on age group 30-55 years. |
Regional Universities Forum for Capacity Building in Agriculture |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
